Novo Nordisk invests more than 16B Danish kroner in production in France

Novo Nordisk announced the investment of more than 16B Danish kroner, or 2.1B euros, starting in 2023 to expand the existing production site in Chartres, France, for the current and future product portfolio within serious chronic diseases. “The investment will significantly increase the capacity of the manufacturing site, adding aseptic production and finished production processes and an extension of the current Quality Control Laboratory. The investment, which includes capacity for GLP-1 products, will increase Novo Nordisk’s ability to meet future demands for innovative medicines,” the company said. “This significant investment announced today confirms the importance of our French manufacturing site, one of our strategic production sites, as a cornerstone of the growth we are experiencing as a company. By maximising the skills and infrastructure we already have on the site, we are expanding our capacity in an efficient way”, added Lone Charlotte Larsen, corporate vice president of Novo Nordisk Production Chartres. The construction projects have now been initiated and will gradually be finalized from 2026 to 2028. The investment is expected to create more than 500 new jobs to run production activities 24/7 when the construction is completed, and the facilities are finalized. During the construction phase, up to 2,000 external employees will be employed.